Synthesis and structure–activity relationship studies of MI-2 analogues as MALT1 inhibitors

Guolin Wu, Haixia Wang, Wenhui Zhou, Bihua Zeng, Wenhui Mo, Kejie Zhu, Rong Liu, Jia Zhou, Ceshi Chen, Haijun Chen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Recent studies revealed that MALT1 is a promising therapeutic target for the treatment of ABC-DLBCL. Among several reported MALT1 inhibitors, MI-2 as an irreversible inhibitor represents a new class of ABC-DLBCL therapeutics. Due to its inherent potential cross-reactivity, further structure–activity relationship (SAR) study is imperative. In this work, five focused compound libraries based on the chemical structure of MI-2 are designed and synthesized. The systematic SARs revealed that the side chain of 2-methoxyethoxy has little impact on the activity and can be replaced by other functionalized groups, providing new MI-2 analogues with retained or enhanced potency. Compounds 81–83 with terminal hydroxyl group as side chain displayed enhanced activities against MALT1. Replacement of triazole core with pyrazole is also tolerant, while structural modifications on other sites are detrimental. These findings will facilitate further development of small-molecule MALT1 inhibitors.

Original languageEnglish (US)
JournalBioorganic and Medicinal Chemistry
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Triazoles
Hydroxyl Radical
Molecules
Libraries
Therapeutics
pyrazole

Keywords

  • Cancer therapeutics
  • MALT1
  • MI-2 analogues
  • Structure–activity relationships

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Synthesis and structure–activity relationship studies of MI-2 analogues as MALT1 inhibitors. / Wu, Guolin; Wang, Haixia; Zhou, Wenhui; Zeng, Bihua; Mo, Wenhui; Zhu, Kejie; Liu, Rong; Zhou, Jia; Chen, Ceshi; Chen, Haijun.

In: Bioorganic and Medicinal Chemistry, 01.01.2018.

Research output: Contribution to journalArticle

Wu, Guolin ; Wang, Haixia ; Zhou, Wenhui ; Zeng, Bihua ; Mo, Wenhui ; Zhu, Kejie ; Liu, Rong ; Zhou, Jia ; Chen, Ceshi ; Chen, Haijun. / Synthesis and structure–activity relationship studies of MI-2 analogues as MALT1 inhibitors. In: Bioorganic and Medicinal Chemistry. 2018.
@article{7e420ce8529b4e82a607e00b43c36249,
title = "Synthesis and structure–activity relationship studies of MI-2 analogues as MALT1 inhibitors",
abstract = "Recent studies revealed that MALT1 is a promising therapeutic target for the treatment of ABC-DLBCL. Among several reported MALT1 inhibitors, MI-2 as an irreversible inhibitor represents a new class of ABC-DLBCL therapeutics. Due to its inherent potential cross-reactivity, further structure–activity relationship (SAR) study is imperative. In this work, five focused compound libraries based on the chemical structure of MI-2 are designed and synthesized. The systematic SARs revealed that the side chain of 2-methoxyethoxy has little impact on the activity and can be replaced by other functionalized groups, providing new MI-2 analogues with retained or enhanced potency. Compounds 81–83 with terminal hydroxyl group as side chain displayed enhanced activities against MALT1. Replacement of triazole core with pyrazole is also tolerant, while structural modifications on other sites are detrimental. These findings will facilitate further development of small-molecule MALT1 inhibitors.",
keywords = "Cancer therapeutics, MALT1, MI-2 analogues, Structure–activity relationships",
author = "Guolin Wu and Haixia Wang and Wenhui Zhou and Bihua Zeng and Wenhui Mo and Kejie Zhu and Rong Liu and Jia Zhou and Ceshi Chen and Haijun Chen",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.bmc.2018.04.059",
language = "English (US)",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Synthesis and structure–activity relationship studies of MI-2 analogues as MALT1 inhibitors

AU - Wu, Guolin

AU - Wang, Haixia

AU - Zhou, Wenhui

AU - Zeng, Bihua

AU - Mo, Wenhui

AU - Zhu, Kejie

AU - Liu, Rong

AU - Zhou, Jia

AU - Chen, Ceshi

AU - Chen, Haijun

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Recent studies revealed that MALT1 is a promising therapeutic target for the treatment of ABC-DLBCL. Among several reported MALT1 inhibitors, MI-2 as an irreversible inhibitor represents a new class of ABC-DLBCL therapeutics. Due to its inherent potential cross-reactivity, further structure–activity relationship (SAR) study is imperative. In this work, five focused compound libraries based on the chemical structure of MI-2 are designed and synthesized. The systematic SARs revealed that the side chain of 2-methoxyethoxy has little impact on the activity and can be replaced by other functionalized groups, providing new MI-2 analogues with retained or enhanced potency. Compounds 81–83 with terminal hydroxyl group as side chain displayed enhanced activities against MALT1. Replacement of triazole core with pyrazole is also tolerant, while structural modifications on other sites are detrimental. These findings will facilitate further development of small-molecule MALT1 inhibitors.

AB - Recent studies revealed that MALT1 is a promising therapeutic target for the treatment of ABC-DLBCL. Among several reported MALT1 inhibitors, MI-2 as an irreversible inhibitor represents a new class of ABC-DLBCL therapeutics. Due to its inherent potential cross-reactivity, further structure–activity relationship (SAR) study is imperative. In this work, five focused compound libraries based on the chemical structure of MI-2 are designed and synthesized. The systematic SARs revealed that the side chain of 2-methoxyethoxy has little impact on the activity and can be replaced by other functionalized groups, providing new MI-2 analogues with retained or enhanced potency. Compounds 81–83 with terminal hydroxyl group as side chain displayed enhanced activities against MALT1. Replacement of triazole core with pyrazole is also tolerant, while structural modifications on other sites are detrimental. These findings will facilitate further development of small-molecule MALT1 inhibitors.

KW - Cancer therapeutics

KW - MALT1

KW - MI-2 analogues

KW - Structure–activity relationships

UR - http://www.scopus.com/inward/record.url?scp=85046827066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046827066&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2018.04.059

DO - 10.1016/j.bmc.2018.04.059

M3 - Article

C2 - 29751989

AN - SCOPUS:85046827066

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

ER -